Pulse Biosciences Shares Jump 51% on nPulse Catheter AF Data
Pulse Biosciences shared clinical data from its nPulse Cardiac Catheter first‐in‐human feasibility study showing successful atrial fibrillation treatment in 150 patients with minimal adverse effects, driving shares 51% higher. The stock trades 49% above its 20-day average with an RSI of 75.6, signaling strong momentum but potential overextension.
1. First‐in‐Human Feasibility Study
Pulse Biosciences presented data showing its nPulse Cardiac Catheter successfully treated atrial fibrillation in 150 patients, with rapid procedure times and minimal adverse events. These results, unveiled at the Annual AF Symposium, highlight the technology’s potential to streamline ablation therapy and improve patient outcomes.
2. Stock Momentum and Technicals
Shares surged over 51%, trading 49% above the 20-day simple moving average and 39.4% above the 100-day average. The RSI of 75.62 indicates overbought conditions while a bullish MACD suggests positive momentum, with key resistance at $24.50 and support at $20.00.
3. Path to Pivotal IDE Trial
Following the successful feasibility study, the company is set to initiate a pivotal IDE clinical trial to treat additional patients and gather data required for regulatory approval and broader market adoption.